Payment overview · 2025
General Payments
$1,278.72
42 reported records · 18 companies
Healthcare provider profile · identity verified
Alex Aurelio Sanchez, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · ELGIN, IL · NPI 1811164916
Verified facts
What the public records show
CMS Open Payments records show Alex Aurelio Sanchez, M.D. received $1,278.72 in general payments during 2025 across 42 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Fanapt, Farxiga, Jardiance, Mounjaro, Ozempic, Xifaxan.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 717 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 717 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Xifaxan by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.04 | 20.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.51 | 13.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $148.00 | 11.6% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $140.12 | 11.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.57 | 7.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $94.31 | 7.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.65 | 4.0% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $49.05 | 3.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.48 | 3.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.91 | 3.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.36 | 2.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.92 | 2.0% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.29 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.34 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.13 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.16 | 1.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.03 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.85 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,278.72 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $261.04 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $175.72 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $140.12 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $118.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $97.57 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $88.24 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $88.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $65.68 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $58.06 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $57.52 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $42.56 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.57 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.27 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $25.92 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 717 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
717 | 88 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
717 | 88 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2285 | 273 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1282 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 1271 | 143 |
| Furosemide | Furosemide | 1146 | 147 |
| Gabapentin | Gabapentin | 1098 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 915 | 93 |
| Sertraline Hcl | Sertraline Hcl | 872 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 847 | 93 |
| Quetiapine Fumarate | Quetiapine Fumarate | 816 | 75 |
| Lisinopril | Lisinopril | 792 | 111 |
| Memantine Hcl | Memantine Hcl | 769 | 61 |
| Donepezil Hcl | Donepezil Hcl | 758 | 58 |
| Eliquis | Apixaban | 717 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 687 | 112 |
| Mirtazapine | Mirtazapine | 641 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 618 | 106 |
| Losartan Potassium | Losartan Potassium | 605 | 86 |
| Potassium Chloride | Potassium Chloride | 599 | 98 |
| Omeprazole | Omeprazole | 562 | 93 |
| Metformin Hcl | Metformin Hcl | 537 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 485 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 471 | 59 |
| Carvedilol | Carvedilol | 415 | 52 |
| Risperidone | Risperidone | 376 | 22 |
| Trazodone Hcl | Trazodone Hcl | 371 | 55 |
| Famotidine | Famotidine | 340 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 292 | 41 |
| Bumetanide | Bumetanide | 267 | 35 |
| Allopurinol | Allopurinol | 255 | 28 |
| Xarelto | Rivaroxaban | 254 | 26 |
| Warfarin Sodium | Warfarin Sodium | 249 | 14 |
| Finasteride | Finasteride | 239 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 234 | 39 |
| Montelukast Sodium | Montelukast Sodium | 234 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 233 | 70 |
| Simvastatin | Simvastatin | 231 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 31 |
| Levetiracetam | Levetiracetam | 219 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 191 | 13 |
| Spironolactone | Spironolactone | 188 | 37 |
| Latanoprost | Latanoprost | 179 | 33 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 175 | 21 |
| Klor-Con M20 | Potassium Chloride | 162 | 13 |
| Divalproex Sodium | Divalproex Sodium | 153 | 21 |
| Gemtesa | Vibegron | 147 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 146 | 15 |
| Enoxaparin Sodium | Enoxaparin Sodium | 143 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 142 | suppressed |
| Baclofen | Baclofen | 141 | 18 |
| Buspirone Hcl | Buspirone Hcl | 140 | 21 |
| Midodrine Hcl | Midodrine Hcl | 135 | 32 |
| Jardiance | Empagliflozin | 131 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 126 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 122 | 58 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 121 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 12 |
| Glipizide | Glipizide | 118 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 115 | 58 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 114 | 42 |
| Alendronate Sodium | Alendronate Sodium | 112 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 111 | 65 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 44 |
| Brimonidine Tartrate | Brimonidine Tartrate | 104 | 15 |
| Ezetimibe | Ezetimibe | 104 | 16 |
| Prednisone | Prednisone | 103 | 37 |
| Nystatin | Nystatin | 98 | 53 |
| Lactulose | Lactulose | 94 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 93 | 14 |
| Nifedipine Er | Nifedipine | 88 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 87 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 35 |
| Bethanechol Chloride | Bethanechol Chloride | 77 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 77 | 31 |
| Meloxicam | Meloxicam | 74 | 11 |
| Topiramate | Topiramate | 74 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 48 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 17 |
| Metolazone | Metolazone | 68 | 11 |
| Torsemide | Torsemide | 68 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 67 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 14 |
| Metformin Hcl Er | Metformin Hcl | 66 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 12 |
| Clonidine Hcl | Clonidine Hcl | 65 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 65 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | suppressed |
| Cephalexin | Cephalexin | 64 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 23 |
| Paliperidone Er | Paliperidone | 63 | suppressed |
| Primidone | Primidone | 63 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 61 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 60 | 19 |
| Xifaxan | Rifaximin | 60 | suppressed |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 12 |
| Humalog | Insulin Lispro | 56 | 14 |
| Januvia | Sitagliptin Phosphate | 55 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | suppressed |
| Novolog Flexpen | Insulin Aspart | 54 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | suppressed |
| Ibuprofen | Ibuprofen | 53 | 20 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 53 | 16 |
| Calcium Acetate | Calcium Acetate | 52 | suppressed |
| Olanzapine | Olanzapine | 52 | 13 |
| Ondansetron Odt | Ondansetron | 52 | 17 |
| Nyamyc | Nystatin | 51 | 18 |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Acyclovir | Acyclovir | 49 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Sucralfate | Sucralfate | 49 | suppressed |
| Digoxin | Digoxin | 48 | suppressed |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Glimepiride | Glimepiride | 47 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 47 | suppressed |
| Timolol Maleate | Timolol Maleate | 47 | suppressed |
| Azithromycin | Azithromycin | 45 | 31 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 45 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Tradjenta | Linagliptin | 45 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 44 | suppressed |
| Nystop | Nystatin | 44 | 29 |
| Valsartan | Valsartan | 44 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 17 |
| Jantoven | Warfarin Sodium | 43 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 42 | suppressed |
| Hydrocortisone | Hydrocortisone | 42 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | suppressed |
| Lovastatin | Lovastatin | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Novolog | Insulin Aspart | 41 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 18 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 34 |
| Dorzolamide Hcl | Dorzolamide Hcl | 38 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Calcitriol | Calcitriol | 37 | suppressed |
| Glipizide Er | Glipizide | 37 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Atenolol | Atenolol | 36 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 36 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 35 | suppressed |
| Amantadine | Amantadine Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 17 |
| Lorazepam | Lorazepam | 33 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | 17 |
| Lidocaine | Lidocaine | 32 | 11 |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 32 | 18 |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Hydroxyurea | Hydroxyurea | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 11 |
| Brilinta | Ticagrelor | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Insulin Lispro | Insulin Lispro | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 14 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 29 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | 14 |
| Permethrin | Permethrin | 28 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Enulose | Lactulose | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 26 | 20 |
| Fiasp | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Budesonide | Budesonide | 25 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | 11 |
| Erythromycin | Erythromycin Base | 23 | 14 |
| Fingolimod | Fingolimod Hcl | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 20 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 20 | suppressed |
| Admelog Solostar | Insulin Lispro | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 18 | suppressed |
| Travoprost | Travoprost | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 14 |
| Diazepam | Diazepam | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 17 | 13 |
| Trimethoprim | Trimethoprim | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Letrozole | Letrozole | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 11 |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Meropenem | Meropenem | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Atropine Sulfate | Atropine Sulfate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Fanapt | Iloperidone | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Propylthiouracil | Propylthiouracil | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,278.72 · 42 records | Novo Nordisk Inc | AUSTEDO XR, BREZTRI, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, INGREZZA, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, XIFAXAN, YUPELRI, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error